Fusion Antibodies PLC
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and … Read more
Fusion Antibodies PLC (FAB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.792x
Based on the latest financial reports, Fusion Antibodies PLC (FAB) has a cash flow conversion efficiency ratio of -0.792x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-575.00K) by net assets (GBX726.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Fusion Antibodies PLC - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Fusion Antibodies PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Fusion Antibodies PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fusion Antibodies PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MCB GROUP LTD (PREF)
SEM:MCBG-P
|
N/A |
|
GTFN Holdings Inc
PINK:BTOW
|
0.065x |
|
Polyplex (Thailand) PCL
STU:PKW
|
0.032x |
|
ADVANCED CELL TECH
BE:T2N
|
N/A |
|
Khonburi Sugar Power Plant Infrastructure Fund
BK:KBSPIF
|
0.024x |
|
Sky Century Investment Inc
PINK:SKYI
|
0.020x |
|
Issara Real Estate Investment Trust
BK:ISSARA
|
0.015x |
|
Azam Jaya Berhad
KLSE:5329
|
N/A |
Annual Cash Flow Conversion Efficiency for Fusion Antibodies PLC (2015–2025)
The table below shows the annual cash flow conversion efficiency of Fusion Antibodies PLC from 2015 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | GBX669.00K | GBX-1.36 Million | -2.039x | -106.65% |
| 2024-03-31 | GBX1.79 Million | GBX-1.77 Million | -0.987x | +36.87% |
| 2023-03-31 | GBX1.12 Million | GBX-1.75 Million | -1.563x | -1644.63% |
| 2022-03-31 | GBX3.68 Million | GBX-330.00K | -0.090x | +63.06% |
| 2021-03-31 | GBX4.75 Million | GBX-1.15 Million | -0.242x | -602.87% |
| 2020-03-31 | GBX4.81 Million | GBX-166.00K | -0.034x | +83.18% |
| 2019-03-31 | GBX5.35 Million | GBX-1.10 Million | -0.205x | -1847.36% |
| 2018-03-31 | GBX6.58 Million | GBX77.19K | 0.012x | +153.59% |
| 2017-03-31 | GBX1.71 Million | GBX-37.37K | -0.022x | -109.21% |
| 2016-03-31 | GBX1.46 Million | GBX346.57K | 0.238x | +122.12% |
| 2015-03-31 | GBX169.29K | GBX-182.05K | -1.075x | -- |